NIH conference. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection.
about
Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope proteinPresence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionThe origins of the human immunodeficiency viruses: an update.Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzeesAdenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.Biochemical analysis of class I and class II MHC antigens in cynomolgus macaques by one-dimensional isoelectric focusing.Genitourinary medicine and sexually transmitted diseases in the 1990s.Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection.Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity.
P2860
Q33880904-BAF718A4-E8F3-407E-8213-73FB11120452Q34171623-BC711D03-A265-4C20-9C8F-735024D6EF3EQ34787140-DC7A4EC5-5870-4457-A882-BA6F9EADC97FQ35224610-31B8462A-4310-410F-8D08-FBB150E396C6Q36197626-56BF8D16-C3AD-4F1F-849A-82E5470AB71FQ36625106-72582EF7-CBCB-4FAE-928B-2F018398D320Q36800188-34CCB520-1DE1-46B8-8E06-11BA75A0AF5EQ37164192-FE8C79C4-45C4-47EE-9C01-FE401E3FA1F9Q39579497-EF533044-8D75-4A06-A5BD-6273ED356861Q44307835-B41FB695-7323-461D-A441-DA2CC2B7B6BFQ44582562-2AB344BE-7CBF-4CB2-9C01-653F1797297CQ45856052-AF333D5E-741F-4B13-AAA0-1204F8268A43Q45873060-4630539F-4DA1-4D87-B939-B75FA353A8CB
P2860
NIH conference. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
NIH conference. Development an ...... iciency virus (HIV) infection.
@en
type
label
NIH conference. Development an ...... iciency virus (HIV) infection.
@en
prefLabel
NIH conference. Development an ...... iciency virus (HIV) infection.
@en
P2093
P1476
NIH conference. Development an ...... iciency virus (HIV) infection.
@en
P2093
P304
P356
10.7326/0003-4819-110-5-373
P407
P577
1989-03-01T00:00:00Z